Clover Biopharmaceuticals Sets 25 Aug 2026 Board Meeting to Approve 1H26 Results and Mull Interim Dividend

Bulletin Express08-13

Clover Biopharmaceuticals has scheduled a board meeting for Tuesday, 25 August 2026 in Shanghai. Directors will review and approve the consolidated interim results for the six months ended 30 June 2026 and decide whether to recommend an interim dividend.

The meeting will also authorize publication of the interim financial statements after board approval. Chairman Dr. Peng Liang will preside, joined by executive director Mr. Joshua G. Liang, non-executive directors Dr. Xiaodong Wang and Dr. Donna Marie Ambrosino, and independent non-executive directors Dr. Xiaobin Wu, Mr. Xiang Liao, Mr. Jeffrey Farrow and Mr. Thomas Leggett.

The announcement underscores the company’s regular financial reporting schedule and signals that any potential dividend decision will be disclosed following the board’s deliberations.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1198595840?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-13 17:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1198595840","market":"hk","top_or_hot":-1,"title":"Clover Biopharmaceuticals Sets 25 Aug 2026 Board Meeting to Approve 1H26 Results and Mull Interim Dividend","media":"Bulletin Express","content":"<p>Clover Biopharmaceuticals has scheduled a board meeting for Tuesday, 25 August 2026 in Shanghai. Directors will review and approve the consolidated interim results for the six months ended 30 June 2026 and decide whether to recommend an interim dividend.</p>\n<p>The meeting will also authorize publication of the interim financial statements after board approval. Chairman Dr. Peng Liang will preside, joined by executive director Mr. Joshua G. Liang, non-executive directors Dr. Xiaodong Wang and Dr. Donna Marie Ambrosino, and independent non-executive directors Dr. Xiaobin Wu, Mr. Xiang Liao, Mr. Jeffrey Farrow and Mr. Thomas Leggett.</p>\n<p>The announcement underscores the company’s regular financial reporting schedule and signals that any potential dividend decision will be disclosed following the board’s deliberations.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Clover Biopharmaceuticals Sets 25 Aug 2026 Board Meeting to Approve 1H26 Results and Mull Interim Dividend</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClover Biopharmaceuticals Sets 25 Aug 2026 Board Meeting to Approve 1H26 Results and Mull Interim Dividend\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-08-13 17:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Clover Biopharmaceuticals has scheduled a board meeting for Tuesday, 25 August 2026 in Shanghai. Directors will review and approve the consolidated interim results for the six months ended 30 June 2026 and decide whether to recommend an interim dividend.</p>\n<p>The meeting will also authorize publication of the interim financial statements after board approval. Chairman Dr. Peng Liang will preside, joined by executive director Mr. Joshua G. Liang, non-executive directors Dr. Xiaodong Wang and Dr. Donna Marie Ambrosino, and independent non-executive directors Dr. Xiaobin Wu, Mr. Xiang Liao, Mr. Jeffrey Farrow and Mr. Thomas Leggett.</p>\n<p>The announcement underscores the company’s regular financial reporting schedule and signals that any potential dividend decision will be disclosed following the board’s deliberations.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02197","symbol_name":"三叶草生物-B","start_time":0,"source_url":"","article_id":"1198595840","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1198595840","pubTimestamp":1786612025,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Clover Biopharmaceuticals has scheduled a board meeting for Tuesday, 25 August 2026 in Shanghai. Directors will review and approve the consolidated interim results for the six months ended 30 June...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02197":"三叶草生物-B"},"translate_title":"Clover Biopharmaceuticals 定于 2026 年 8 月 25 日召开董事会会议，批准 26 年上半年业绩并考虑中期股息","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02197":1},"content_text":"Clover Biopharmaceuticals has scheduled a board meeting for Tuesday, 25 August 2026 in Shanghai. Directors will review and approve the consolidated interim results for the six months ended 30 June 2026 and decide whether to recommend an interim dividend.\nThe meeting will also authorize publication of the interim financial statements after board approval. Chairman Dr. Peng Liang will preside, joined by executive director Mr. Joshua G. Liang, non-executive directors Dr. Xiaodong Wang and Dr. Donna Marie Ambrosino, and independent non-executive directors Dr. Xiaobin Wu, Mr. Xiang Liao, Mr. Jeffrey Farrow and Mr. Thomas Leggett.\nThe announcement underscores the company’s regular financial reporting schedule and signals that any potential dividend decision will be disclosed following the board’s deliberations.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.48.0","shortVersion":"4.48.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1198595840","isCrawlerRequest":true}